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What is known on the subject?  
 People with severe mental illness (SMI) have a life expectancy 15-20 years less than the 
general population, partly due to increased risk of physical disease, including type II diabetes 
(T2DM) and cardiovascular disease. 
 Little is known about changes in cardiovascular risk factors over time in people with both 
T2DM and SMI compared to those with T2DM and no SMI. 
What this paper adds to existing knowledge? 
 We investigated whether levels of cardiovascular risk factors, cholesterol, HbA1c, systolic and 
diastolic blood pressure associated with adverse clinical outcomes are different in T2DM 
patients with and without SMI. We found significant differences in systolic blood pressure 
and HbA1c between the two groups. 
 55% and 29% of T2DM patients with comorbid SMI are at increased risk of adverse clinical 
outcomes due to sub-optimal HbA1c and systolic blood pressure levels respectively. 
What are the implications for practice?   
 Many patients with T2DM and SMI have higher levels of cardiovascular risk compared to 
patients with T2DM only, and good management of risk factors is therefore particularly 
important in patients with both conditions. 
 Achieving better control of HbA1c levels is likely to be central to addressing inequalities in 







Introduction: Patients with both severe mental illness (SMI) and type II diabetes (T2DM) have lower 
life expectancy than patients with T2DM alone, partly due to poor control of cardiovascular risk 
factors in comorbid patients. 
Aim: To compare levels of cholesterol, HbA1c and blood pressure in T2DM patients with and without 
SMI. 
Method: We analysed longitudinal clinical records of 30,353 people with T2DM (657 with SMI;29,696 
controls without SMI) between 2001 and 2013 using the Clinical Practice Research Datalink (CPRD). 
We used mixed effects regression models to compare cardiovascular risk factors between SMI and 
controls.  
Results: Patients with SMI had lower mean systolic blood pressure (SBP) (β -2.49; SE=0.45 P=<0.01) 
and were more likely to have extreme (high and low) values of HbA1c and SBP (OR 1.38, 95%CI: 
1.16,1.64 and 1.76:1.40,2.21 respectively). 
Discussion: People with T2DM and SMI have similar average values of cardiovascular risk factors to 
people with T2DM alone but are more likely to have values of HbA1c and SBP indicating increased 
risk of adverse clinical outcomes.  
Implications for Practice:  Improved management of cardiovascular risk factors in general, glycaemic 
control in particular, is central to addressing the increased risk of adverse outcomes in people with 
both SMI and T2DM. 
Keywords: Epidemiology, Physical Health, Primary Care 
Relevance statement  
People with comorbid T2DM and SMI are more likely to have extreme values of HbA1c and systolic 
blood pressure that are associated with adverse clinical outcomes. Better management of these risk 
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factors should be ensured to address inequalities in physical health outcomes in patients with SMI 
and T2DM. 
Introduction 
People with severe mental illness (SMI) including schizophrenia, bipolar disorder and other forms of 
psychosis have a life expectancy 15-20 years less than the general population (Brown et al., 2010). 
Reduction of excess mortality in those with mental disorders has been identified as an important 
global health issue, identifying risk factors for earlier mortality can lead to development of effective 
interventions to address physical health inequality among those with mental disorder (Liu et al., 
2017). Most of the premature deaths are caused by complications of physical health conditions 
(Reilly et al., 2015, De Hert et al., 2009). These include insulin resistance and relative insulin 
deficiency forms of diabetes mellitus, type II diabetes mellitus (T2DM), the prevalence of which is 
twice as great in those with SMI than in the general population (Reilly et al., 2015). This increased 
prevalence of T2DM is attributed due to a variety of factors including genetic predisposition (De Hert 
et al., 2009), the metabolic effects of atypical antipsychotics (Smith et al., 2008), higher levels of 
obesity and poor diet (Osborn et al., 2007), lower levels of physical activity (Daumit et al., 2005) and 
the greater barriers that disadvantaged or marginalised groups face in navigating the healthcare 
system (Dixon-Woods et al., 2006). People with the co-occurrence of T2DM and SMI (comorbid 
T2DM and SMI) have around a 50% increased risk of mortality compared with people with T2DM 
alone (Kontopantelis et al., 2015, Wu et al., 2015, Vinogradova et al., 2010), but the underlying 
mechanism for this difference is not well understood. Candidate causes include higher levels of 
smoking (McDonald, 2000), poor management of cardiovascular risk factors (including glycaemia, 
cholesterol and blood pressure), and higher prevalence of other comorbid conditions (Vinogradova 
et al., 2010). Patients with comorbid SMI and T2DM are less likely to receive standard levels of 
diabetes care, with 45% not receiving any diabetes care and the least chance of receiving specialised 
interventions for cardiovascular treatments (De Hert et al., 2011). Controlling HbA1c and optimising 
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lipid and blood pressure management reduces the risks of microvascular and macrovascular 
complications, which remain the main cause of morbidity and mortality in patients with T2DM (Ray 
et al., 2009, Khaw et al., 2001, Collaborators, 2008, Group, 1998). However, the evidence for 
appropriate management of cardiovascular risk factors in patients with diabetes and SMI is 
inconclusive, particularly in the UK (Dixon et al., 2004, Wake et al., 2016). A small study in the United 
States showed that patients with SMI had lower levels of HbA1c compared to patients without SMI 
(Dixon et al., 2004), and a recent larger study suggested that people with T2DM taking antipsychotic 
medication have lower cholesterol, HbA1c and blood pressure levels compared to matched controls 
not taking antipsychotic medication (Wake et al., 2016). There is, however, little evidence at a 
population level on the changes in cardiovascular risk factors over time in those with SMI that 
develop T2DM compared to those with T2DM and no SMI. Using population level data of clinical 
records from primary care, we can assess variation in cardiovascular risk factors that may be a 
contributing factor to the excess mortality for people with SMI and T2DM at a population level.  
Identification of the candidate causes of the mortality gap can then be targeted through evidence-
based interventions (Lawrence and Kisely, 2010).       
The aim of this study was to investigate whether there is a difference in cardiovascular risk factors in 
adults with diabetes and SMI compared with adults with diabetes without SMI, and whether these 
risk factors change over time.  
 
Materials and Methods 
Data Source  
We used data from Clinical Practice Research Datalink (CPRD) which contains primary care records 
for around 6.9% of the UK’s patients (Herrett et al., 2015). Clinical care processes, diagnoses, 
measurements and test results are recorded using a hierarchical set of clinical codes (Read codes). 
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Prescriptions for medicine are recorded using British National Formulary (BNF) codes. The sample 
used in this study was taken from 125 out of 674 practices in CPRD (19%), all practice included in the 
sample were based in England. Practices were selected to be proportionally representative of the 
proportional distribution of all the 674 practices in CPRD in terms of level of socioeconomic 
deprivation (using practice postcode linked to Index of Multiple Deprivation) and practice size in 
terms of number of registered patients. All patients’ records at participating practices were added to 
the CPRD database, the criteria for inclusion in our sample were patients with at least one of the 
following long-term conditions documented using Read codes in their primary care record: asthma, 
atrial fibrillation, coronary heart disease (CHD), chronic kidney disease (CKD), chronic obstructive 
pulmonary disease (COPD), diabetes, epilepsy, heart failure, hypertension, hyperthyroidism, learning 
disability, osteoporosis, SMI or stroke. For the purpose of this study, we selected all patients in the 
sample who had diabetes, with or without other long-term conditions. 
Cohort 
Patient records were included in the study if they had a Read code indicating a diagnosis of T2DM. 
Patients with diabetes diagnosis Read codes that did not distinguish diabetes type were excluded. 
Patients with SMI were identified using Read codes indicating a diagnosis of SMI (schizophrenia, 
bipolar disorder or other forms of psychoses). Patients with T2DM but without SMI were classified as 
controls. Patients with diagnosis dates for either condition that matched their date of entry into a 
CPRD practice (1% of all patients) were excluded from the analysis as their diagnosis date was not 
deemed reliable, as this suggests the diagnosis was made prior to the patient joining the study 
practice. 
Data were extracted for 1st April 2001 to 31st March 2013. Not all participants entered the study in 
2001; for patients with both SMI and type II diabetes (T2DM), patients entered the study on the year 
of their diagnosis of the second condition, either SMI or T2DM, depending on the order in which the 
patient was diagnosed. The year of diagnosis of T2DM was the baseline year in patients without SMI. 
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All eligible patients (18+ years) upon entering the database were followed up until the end of the 
study (2013), unless they died or moved to a non-study practice.  
 
Outcomes 
Diabetes-related measurements included serum cholesterol levels, HbA1c levels, and systolic and 
diastolic blood pressure (SBP and DBP respectively), which are predictive of future complications 
(Ray et al., 2009, Khaw et al., 2001, Collaborators, 2008, Group, 1998). National guidelines generally 
aim to control these parameters below recommended thresholds, but previous studies have 
suggested that very low levels of these parameters are not always associated with optimal 
outcomes. We therefore examined both mean levels of these parameters and values identified in 
previous studies as being associated with increased risk of mortality in patients with diabetes: HbA1c 
<6.25% or >7.75% (<45 or >61mmol/mol), serum cholesterol <2.5mmol/l or >6.5mmol/l , SBP 
<115mmHg and DBP <72.5mmHg or >92.5mmHg (Lipska et al., 2013, Kontopantelis et al., 2015). 
Repeated measures were used for each year for each patient during the study period. When 
multiple values were available in the same year for the same patient, the mean of the patient’s 
values were used.  
Covariates 
Data were extracted from patients’ records for the following covariates: gender, age, body mass 
index (BMI) (Bhaskaran et al., 2013), smoking behaviour, comorbid long-term illnesses, prescription 
of diabetes medication, antipsychotic medication, antidepressant medication and cardiovascular 
medication were recorded if a prescription code was reported at any time within a given year. Area 
deprivation for patient postcode was measured in quintiles using Index of Multiple Deprivation 
(IMD) as a measurement of patients’ socioeconomic status  (Noble et al., 2006). Ethnic group was 
identified using Read codes in patients’ records but because ethnicity is typically poorly reported in 
8 
 
primary care, for those with missing data in CPRD, we acquired the information using Hospital 
Episodes Statistics (HES) using a standardised approach (Mathur et al., 2014). Smoking status was 
taken from the patient’s clinical record. If smoking status was missing in the corresponding year, the 
last recorded smoking status was used from the patient’s historical record. 
Several comorbid conditions were used to control for differences in underlying risk factors between 
those with and without SMI. The comorbid conditions included asthma, coronary heart disease 
(CHD), chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), epilepsy, heart 
failure, hypertension, hyperthyroidism, osteoarthritis (OA), osteoporosis, or stroke.  Read codes to 
identify all diagnoses of health conditions were taken from previously validated lists (Reilly et al., 
2015). All Read code lists used in this study are available to download from www.clinicalcodes.org.  
Statistical analysis 
We calculated proportions or means and standard deviations (SD) for each outcome. Median and 
interquartile ranges (IQR) are reported for skewed data. Characteristics of adults with SMI and 
controls are presented as measured at baseline year. Between-group differences were assessed over 
the whole study period using χ2 test for proportions. Student’s paired t-test was used to compare 
mean values and Wilcoxon rank sum test was used for skewed data. Differences in prevalence of 
comorbidities were compared using a logistic regression whilst adjusting for age and gender.  
We used a two-level linear mixed model for each continuous variable (cholesterol, HbA1c, SBP or 
DBP), reporting beta (β) and its standard error (SE), and to examine high risk values we used two-
level logistic mixed effects models for each outcome, reporting odds ratios (OR) and 95% confidence 
intervals (95% CI). Results of the regression models are reported over the whole study of all patients. 
We also describe changes over time in both groups over the course of each year of follow up. The 
linear and logistic mixed effects models were specified to the following nested structure: nested 
within different general practices (level 1) and individuals over time (level 2); hence, individual-level 
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and practice level random intercepts and individual random slopes were specified in the model. We 
fitted increasingly complex models: 1) bivariate model; 2) multivariate model which also adjusted for 
mean age (in years), gender, ethnicity, socioeconomic status (the most affluent quintile as the 
reference group), mean BMI, presence or absence of comorbidities, and smoking status as 
covariates; 3) as model 2 plus number of years of diabetes diagnosis and presence or absence of 
cardiovascular medication that interacts with cholesterol (statins and other lipid lowering agents) 
and blood pressure (ACE inhibitors, α blockers, β blockers, calcium channel blocker, thiazide diuretic, 
loop diuretics, other lipid lowering and statins). We did not explore the confounding effect of SMI 
patients taking antipsychotic medication or mood-stabilisers on outcomes because only a very small 
proportion of our control group had been prescribed antipsychotics or mood-stabilisers, compared 
to nearly half of those in the SMI group leading to co-linearity between antipsychotic medication or 
mood-stabilisers and diagnosis of SMI in our cohort. 
Due to the nature of the CPRD data and the statistical models used, data were not considered 
missing for medication and comorbidities, as the absence of a Read code may identify the patients 
as not having a diagnosis of a condition or prescription of medication in the given year and could not 
be used to distinguished missing data. Missing data were only considered where records were 
missing for BMI, smoking, ethnicity, cholesterol, HbA1c, SBP or DBP. There was no difference in the 
proportion of patients in each group with missing data (supplement 1). To account for missing data, 
we used multiple imputations using a chained command (MICE) and presented the imputed results 
as the main analysis (White et al., 2011). The MICE repeatedly sampled from the distribution of the 
four outcome variables: cholesterol, HbA1c, SBP and DBP and all other covariates included in model 3 
were entered to the imputation model. Sensitivity analysis was conducted for complete data in all 
analyses, the statistical significance of analyses was the same in both complete data and imputed 






There was no difference in the proportion of patients in each group with missing measurements of 
cholesterol (df=1, N=3353, X2=1.0, P=0.3), HbA1c (df=1, N=3353, X2=0.6, P=0.4), SBP (df=1, N=3353, 
X2=0.6, P=0.4) or DBP (df=1, N=3353, (X2=1.7, P=0.2) for the study period (supplement 1). Data for 
ethnicity was missing for 16% of patients with SMI and 17% of controls (df=1, N=3353, X2=0.3, 
P=0.6). For BMI and smoking status; 22% of SMI patients and 24% of controls had at least one 
missing value in any one year, again this was not different between groups (df=1, N=3353, X2=0.6, 
P=0.4).  
 
Patient characteristics at baseline year 
There were 30,353 T2DM patients identified within the dataset, with 657 (2%) having a diagnosis of 
SMI. For patients with both conditions, most (73%) were diagnosed with SMI first. The 
characteristics of the cohort are displayed in table 1. Compared to controls, people with SMI and 
T2DM were on average younger, more likely to be female, to live in an area of high deprivation and 
to smoke, and less likely to be of white British ethnicity. Mean BMI was higher in people with SMI. 
Those with SMI were diagnosed with diabetes at a younger age (mean 54.7 years compared to 59.6 
years for controls) but the number of years since diagnosis with diabetes was not significantly 
different.   
Compared to controls, a higher proportion of people in the SMI group had prescriptions for diabetic 
medication and antidepressants, but a lower proportion had prescriptions for cardiovascular 
medication. There was no significant difference in the number of additional comorbidities between 
groups, but people with SMI and T2DM were more likely to have CKD, dementia, depression, 
epilepsy, hypothyroidism or stroke and less likely to have CHD, hypertension or osteoarthritis. There 
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were no significant differences between groups in the prevalence of asthma, cancer, COPD, heart 
failure, or osteoporosis.    
 
Differences in cardiovascular risk factors  
Over the whole follow-up period there were no significant differences between people with SMI and 
controls in mean level of cholesterol (β=-0.05; SE=0.05, P=0.19), HbA1c (-0.08; 0.05, P=0.09) or DBP (-
0.30; 0.25, P=0.21), but mean SBP was significantly lower in people with SMI  (-2.50, 0.44 P≤0.001) 
(table 2). Over the whole study period and controlling for all covariates, people with SMI and T2DM 
were more likely to have higher risk for high or low HbA1c (OR 1.38; 95% CI=1.18, 1.64) (table 2), a 
difference between groups observed in low and high HbA1c values with 55% of people with SMI at 
risk (table 3). There were similar findings for SBP, with difference between groups observed in low 
SBP values (1.76; 1.40, 2.21), with 29% of people with SMI at risk (table 3). There was no statistically 
significant difference between group in cholesterol or DBP in specifications 1, 2 or 3 of the multilevel 
mixed effect binary logistic regression model. Full results of all three models including covariates are 
available in the appendix (supplement 2). 
Changes over time in groups 
Differences for some outcomes, however, changed over time. For cholesterol, mean levels fell in 
both groups over study period (figure 1a). For HBA1c, mean levels in both groups increased over time 
from similar baselines, but levels in the control group increased at a faster rate; after 12 years mean 
levels were higher for controls compared to SMI patients, but this difference failed to reach 
statistical significance (figure 1b). For SBP, mean levels changed over time in both groups, but levels 
were similar in both groups after 12 years (figure 1c). For DBP, mean levels decreased over time in 
both groups, and were not significantly different at any time (figure 1d).  The proportion of all 
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patients in both groups with levels of outcomes associated with a higher risk of adverse events 




When examining differences between groups in the values of cardiovascular risk factors, we found 
that people with SMI had similar mean values of blood cholesterol, HbA1c and DBP. After controlling 
for the confounding effect of difference in patient characteristics, socioeconomic level, medication 
and comorbidities, people with SMI had significantly lower values of SDP compared to controls. In 
relation to values of cardiovascular risk factors associated with increased risk of diabetes 
complications or mortality, people with SMI appear to be more likely to have at-risk values of HbA1c 
due to high and low levels, and SBP due to low levels compared to controls. This suggests that, 
despite similar values in mean scores, a higher proportion of those with low values of cardiovascular 
risk factors in HbA1c and SBP may contribute to the health inequalities in physical health outcomes 
observed for people with SMI and T2DM.  
Study Strengths and limitations  
We analysed a longitudinal dataset containing rich information on individual patients and their 
management within primary care, adjusting for important comorbidities and differences in 
characteristics of the groups of interest. In addition to exploring differences in mean values of 
cardiovascular risk factors, we also examined differences in proportions of patients with risk factor 
levels associated with increased risk of complications and mortality (Kontopantelis et al., 2015). 
Lower values below thresholds of cardiovascular risk factors appear to indicate similar risks for 
microvascular and macrovascular complications in T2DM patients as has been shown in 
cardiovascular factors used for this study, we selected thresholds that represented a significant 
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increased risk of earlier mortality compared to a reference value in a study of 246,544 T2DM 
patients (Kontopantelis et al., 2015). While we considered values of cardiovascular risk factors, it is 
possible that cardiovascular risk factor variability differs between our study groups, glycaemic 
variability, which has been associated with adverse outcome (Cardoso et al., 2018) possibly 
contributes to health inequality in people with SMI and T2DM could be an area of future research.  
This study is the first to explore if those with SMI and T2DM are at increased risk to adverse clinical 
outcomes due to a combination of low or high levels of HBA1c and SBP, compared to only higher as 
previously reported.       
The study has several limitations. First, the number of adults with comorbid SMI and diabetes was 
relatively small and fell during follow-up. Only 5.0% of the SMI cohort remained at 12 years of 
follow-up, compared to 8.9% in the control group. Attrition in this study is primarily due to patients 
entering into the study after 2001, leading to fewer follow up years in these patients. For example, a 
patient with a T2DM diagnosis in 2010 only had a maximum follow-up of 3 years to 2013 (i.e. the 
date of data cut). Other contributions to attrition were patients dropping out from the practice, due 
to mortality or leaving the practice. In addition, two practices included in our sample did not have 
data uploaded to CPRD for the final year of follow up. With a larger sample, we may have been able 
to identify statistically significant differences in markers of cardiovascular risk between the two 
groups, although we would have to consider whether any such differences were clinically 
meaningful. Similarly, our results with respect to the increased risk of extreme values of risk factors 
in patients with SMI may be affected by the relatively small sample. Second, our dataset depends on 
accurate and complete recording by primary care practices and missing data is a particular issue for 
some important covariates, for example ethnicity (Mathur et al., 2014), smoking behaviour, and 
body mass index (Bhaskaran et al., 2013). The proportion of missing data was not found to be 
different between groups. We used multiple imputation to infer robust variances and no differences 
were detected comparing findings drawn from imputed and non-imputed results. Third, although 
the sampled practices were nationally representative in terms of patient demographics, they might 
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not be nationally representative in terms of the quality of management of patients with T2DM 
and/or SMI, although we have no reason to believe that they were not. Fourth, we do not know 
whether the data we analysed were differentially recorded between our study groups, and it is 
possible that adjustment for differences in patient characteristics resulted in residual confounding. 
Fifth, we could only adjust for area-level deprivation which will not have accounted for individual 
differences in socio-economic status. Finally, in our main analysis, duration of follow-up for patients 
without SMI began at the time of diagnosis with diabetes, whereas a quarter of patients with SMI 
had pre-existing diabetes. However, we retained comorbid SMI patients who developed diabetes 
first to analyse all patients with both diagnoses and controlled for duration of illness in our 
regression models. Despite limitations relating to attrition and sample size of comorbid SMI patients 
in the study, the results of differences between groups appears to be robust; where there were no 
statistical differences between groups in the regression models, mean beta and OR suggest no 
differences of clinical importance.     
 
What the study adds to the existing evidence 
We estimate that approximately 55% of T2DM patients with comorbid SMI are at increased risk of 
microvascular and macrovascular complications due to high or low HbA1c levels. This represents a 
higher risk compared to T2DM patients with no SMI. Our analysis of longitudinal data suggests this 
risk remains stable for SMI patients from onset of diagnosis. Approximately 29% of T2DM patients 
with comorbid SMI are also at increased risk due to levels of SBP associated with adverse outcomes, 
again a higher proportion of those at risk compared to T2DM patients with no SMI. To our 
knowledge, this is the first study to explore extreme (high and low) values related to cardiovascular 
risk, the presence of which may be obscured when mean values are examined.      




Our study is the first to comparatively evaluate markers of cardiovascular risk factors in people with 
SMI using longitudinal data. Two previous studies, one a case-control study (matching patients with 
schizophrenia with controls on factors including BMI) and one a cross-sectional study, observed 
significantly lower HbA1c levels in SMI groups compared to non SMI groups (Dixon et al., 2004, Wake 
et al., 2016). We observed no significant initial difference in mean HbA1c between groups, but we 
included patients without schizophrenia and did not follow the same matching approach. We also 
found that over time, HbA1c levels in patients with SMI increased at a slower rate than for patients 
without. The case-control study also compared serum cholesterol levels and blood pressure in 
patients with schizophrenia to controls. The findings were similar to our study; compared with 
controls, average blood pressure was lower in patients with schizophrenia but there were no 
differences for serum cholesterol.   
People with SMI face a greater risk of developing several chronic physical diseases, including 
diabetes, and tend to have poorer outcomes for those conditions compared to the general 
population. Both SMI and diabetes are mainly managed in the community setting in the England, 
and primary care has a central role in coordination and continuity of care for patients with multiple 
conditions (Ricci-Cabello et al., 2015). It is therefore crucial that mental health nurses are aware that 
a higher proportion of their patients with T2DM and SMI are at risk of adverse outcomes due to their 
cardiovascular risk factors. Better management of all cardiovascular risk factors should be ensured, 
particularly controlling of extreme (high and low) values of HbA1c, to address inequalities in physical 
health outcomes in patients with SMI and T2DM. We found that overall the management of 
cardiovascular risk factors was similar in diabetes patients with and without SMI, although those 
with SMI appear to be at increased risk of HbA1c and SBP values associated with increased risk of 
adverse clinical outcomes. However, further investigation of the contributors to the physical health 




Overall, our findings suggest that people with SMI are more likely to have HbA1c and SBP values 
associated with poor cardiovascular outcomes in the context of diabetes. They are also more likely 
to live in deprived areas, to smoke, and to be obese. Conversely, they are less likely to have 
hypertension or coronary heart disease. After controlling for such risk factors, patients with SMI 
have similar average levels of cholesterol, HbA1c and DBP but lower SBP. This suggests that patients 
with SMI and diabetes are managed to a similar standard to other patients with diabetes, and that 
other factors are maybe responsible for the gross inequalities in physical health outcomes observed 
for people with SMI.  However, both HbA1c and SBP in patients with SMI may be over-treated, which 
may increase the risk of adverse clinical outcomes. This warrants further investigation, including the 
contributing factors that increase risk of mortality, microvascular events, macrovascular events and 
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Table 1 Characteristics of cohort at baseline year 
Characteristics  SMI (n=657) Control (n=29 696) P value 
Age years, mean (SD) 59.1 (14.1) 63.6 (13.4)  <0.001* 
Females, n (%) 356 (54) 13267 (45) <0.001** 























IMD quintile, n (%) 






















Mean BMI (kg.m2), mean (SD) 























Age at diabetes diagnosis, 
mean years(SD) 
54.3 (14.5) 56.9 (16.9) <0.001* 
Years since diabetes 
diagnosis, median (IQR) 
1 (1-6) 1(1-5) Z=0.001*** 











Age at SMI diagnosis, mean 
years( SD) 
45.9 (16.6)   
years since onset of SMI 
diagnosis, median years (IQR) 
10 (2-20)   
Diabetes medication, n (%) 
None  
Insulin only 









































Calcium channel blocker 
Thiazide diuretic 
Loop diuretics 






































Lithium or other mood 
stabilizer medication, n (%) 
170(26) 421 (1) <0.001** 

























count, median (IQR) 
1 (0-2) 1 (0-2) Z=0.08*** 
Comorbidities, n (%) 
Asthma 
Cancer 
Coronary heart disease 





























































SMI severe mental illness, BMI body mass index, SD standard deviation, IQR inter quartile range, 
IMD index of multiple deprivation, * t-test, ** χ2 test, *** Wilcoxon rank sum test, **** logistic 
regression adjusting for age and gender. Data for medication categories are not mutually exclusive 
as patients could be prescribed more than one. Comparisons of medication between groups were 
made in those with no reported medication compared to those with at least one medication. 
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Table 2 Beta coefficients and odds ratios for patients with SMI compared to controls from univariate and multivariate multilevel mixed effect regression 
models for cardiovascular risk factors 









0.05 (0.05, 0.31) 
-0.08 (0.05, 0.13) 
-0.07 (0.05, 0.19) 
 
0.04 (0.05, 0.41) 
-0.05 (0.05, 0.32) 
-0.08 (0.05, 0.09) 
 
-4.32 (0.49, <0.001) 
-3.06 (0.46, <0.001) 
-2.49 (0.45, <0.001) 
 
0.10 (0.29, 0.74) 
-0.51 (0.25, 0.04) 
-0.30 (0.25, 0.22) 





















Table 3 Percentage of patient-years with ‘high risk’ levels of outcomes over all patient-years 
 SMI Controls 




0 (0, 1) 
4 (3, 5.) 
 
1 (1, 1) 
3 (3, 3) 
HbA1c, % (95% CI) 
Below 6.25% (<45 mmol/mol) 
Above 7.75% (61mmol/mol) 
 
27 (25, 28) 
32 (30, 34) 
 
19 (19, 20) 
31 (30, 31) 
Systolic, % (95% CI)  
Below 115mmHg 
 
29 (26, 29) 
 
18 (17, 18) 




28 (26, 30) 
4 (3, 4) 
 
30 (30, 30) 









































Figure 2 Percentage of diabetes patients with ‘high risk’ levels of outcomes by year of follow-up  


























(d) Diastolic blood pressure <72.5mmHg or >92.5mmHg 
 
 
 
